AOD-9604 Benefits: Claims vs What Studies Show
Benefits people claim for AOD-9604, set against what published studies measured, and where no study exists.
- Strongest evidence
- Animal
- Human / animal studies
- 0 / 4
- in our evidence file (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- research chemical
Claimed benefits and what studies show
Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Claim | Best evidence | Studies (human / animal) | What was measured | Page |
|---|---|---|---|---|
| Weight loss | Animal evidence, 2 of 4 | 0 / 3 | Body weight gain and fat oxidation; Glucose effects; Body weight and fat | Evidence for weight loss |
Strongest study per claim: Weight loss, International journal of obesity and related metabolic disorders 2001, PMID 11673763.
What the studies measured
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Cartilage regeneration | In rabbits, intra-articular AOD9604 enhanced cartilage regeneration; AOD9604 plus hyaluronic acid worked better than either alone. | Animal · rabbit (not a human result)n = 32 | Annals of clinical and laboratory science 2015, PMID 26275694 |
| Body weight gain and fat oxidation | Both hGH and AOD reduced weight gain in obese mice, with higher fat oxidation and plasma glycerol. | Animal · mouse (not a human result) | International journal of obesity and related metabolic disorders 2001, PMID 11673763 |
| Glucose effects | AOD9604 did not cause hyperglycaemia or reduce insulin secretion, unlike hGH. | Animal · mouse (not a human result) | International journal of obesity and related metabolic disorders 2001, PMID 11673763 |
| Body weight and fat | Both reduced body weight and body fat in obese mice over 14 days. | Animal · mouse (not a human result) | Endocrinology 2001, PMID 11713213 |
| Knock-out mice | In beta(3)-AR knock-out mice long-term treatment did not change body weight as in wild-type. | Animal · mouse (not a human result) | Endocrinology 2001, PMID 11713213 |
| Body weight gain | Oral AOD9604 for 19 days cut body weight gain by over 50% (15.8 g vs 35.6 g control) in obese Zucker rats. | Animal · rat (not a human result) | Hormone research 2000, PMID 11146367 |
| Insulin sensitivity | No adverse effect on insulin sensitivity, unlike intact hGH. | Animal · rat (not a human result) | Hormone research 2000, PMID 11146367 |
The weight-loss claim: rats and mice only
The headline weight claim traces to obese Zucker rats given oral AOD9604 for 19 days, where weight gain fell by over half against control animals. This is rat data, not a result in people.[4]
A second animal result, in obese mice treated through mini-osmotic pumps, found less body weight gain than controls. These are mouse findings and say nothing yet about humans.[2]
The mouse fat-mass claim comes from a 14-day injection study in obese mice, which reported lower body weight and body fat. Again, mice only.[3]
The fat-burning claim, as far as studies went
The 'burns fat' claim rests on obese-mouse work reporting more fat oxidation and lipolysis, and the same abstract says the peptide does not act through the growth hormone receptor. Mouse evidence only.[2]
In the oral rat study, fat tissue taken from the treated animals showed more lipolytic activity than tissue from the controls.[4]
The cartilage and joint claim
Joint-repair claims come from one rabbit knee study with collagenase-induced osteoarthritis, where the authors concluded the injections enhanced cartilage regeneration. It is animal work and cannot be read as a human cartilage result.[1]
What no study shows
A dated PubMed search of AOD-9604 names on 2 October 2026 returned 22 records, and none of them was a human efficacy trial, so the human version of every claim above has no trial behind it on this site.
Calculated from evidence file web/src/data/evidence/aod-9604.json; query AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]; date 2026-10-02; records 22; human efficacy trials 0. Formula: records returned by the search = 22; human efficacy trials among them = 0
A second PubMed query on 11 October 2026 combining AOD-9604 with adverse-event and safety terms returned 6 records, none reporting adverse events seen in people given the peptide.
Calculated from evidence file web/src/data/evidence/aod-9604.json; date 2026-10-11; records 6; reporting adverse events in people 0. Formula: records returned = 6; reports of human adverse events among them = 0
More on AOD-9604
Common questions
Is AOD-9604 proven to work?
The strongest study we summarise for AOD-9604 is animal evidence, among 4 studies. That is not proof it works in people.
What does AOD-9604 do?
The studies cited here are all in animals: they report less weight gain in obese rats and mice, more lipolysis, and in rabbits better knee cartilage scores; no human result is cited.
Calculated from animal studies cited 4; human studies cited 0. Formula: 4 cited studies (rat, mouse, mouse, rabbit); human studies = 0
Does AOD-9604 work for weight loss in people?
The oral rat study reports its authors' reading that the analogue may have potential as a therapeutic agent for obesity, which is a statement about development, not a demonstrated effect in people.[4]
More on AOD-9604
Sources
- 1Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
- 2Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001PMID 11673763Accessed 2 Oct 2026
- 3The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.Endocrinology · 2001PMID 11713213Accessed 2 Oct 2026
- 4Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
- 5PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
Found an error? Report a correction.